Pfizer announced on Thursday that it is progressing the development of a once-daily weight loss pill, which it anticipates could compete in the GLP-1 market. In related news, the U.S. Food and Drug Administration (FDA) did not approve Novo Nordisk’s once-weekly insulin. Furthermore, a report from the U.S. Federal Trade Commission (FTC) revealed that pharmacy benefit managers (PBMs) are increasing drug prices.
These are among some of the key pharmaceutical news highlights this week.